Ipsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders
Ipsen and Skyhawk Therapeutics have entered into an exclusive global partnership to explore and create new small molecules that can influence RNA for rare neurological conditions. Under this agreement, Ipsen has the option to obtain exclusive rights worldwide for developing promising candidates resulting from the collaboration. Once successful candidates are identified, Ipsen will oversee all subsequent activities. Skyhawk's innovative platform expedites the development of small molecules targeting RNA in various therapeutic domains, particularly focusing on rare neurol...